Neuro-Oncology: The Podcast

99 Folgen

1. CSF proteomics in glioma

   Vom: 21.3.2025
2. Vorasidenib in IDH mutant glioma

   Vom: 8.3.2025
3. KL-50 in post TMZ MMR-deficient GBM

   Vom: 22.2.2025
4. Measurable disease per FET-PET vs MRI in GBM

   Vom: 8.2.2025
5. Pre-radiation chemotherapy in GBM

   Vom: 20.1.2025
6. cIMPACT-NOW Update 8: grading of meningiomas

   Vom: 13.12.2024
7. Residual tumor volume and survival after CCNU/TMZ in GBM

   Vom: 24.11.2024
8. Alterations in RNA splicing between meningioma DNA methylation groups

   Vom: 8.11.2024
9. The immune landscape of IDH mutant and IDHwt glioma

   Vom: 25.10.2024
10. Equity-driven applications of AI in neuro-oncology

    Vom: 9.10.2024
11. IDH mutant glioma across age groups

    Vom: 20.9.2024
12. Contemporary molecular prognostic signatures in glioma

    Vom: 30.8.2024
13. FDG PET in PCNSL

    Vom: 9.8.2024
14. TMZ and MGMT in elderly GBM patients

    Vom: 12.7.2024
15. IDH mutant glioma and IDH inhibitors

    Vom: 5.7.2024
16. Leptomeningeal disease, a SNO and ASCO review

    Vom: 28.6.2024
17. Cancer stems cell in GBM

    Vom: 21.6.2024
18. Drug delivery across the blood-brain barrier

    Vom: 13.6.2024
19. Gliomatosis cerebri in children

    Vom: 24.5.2024
20. Immunotherapy drives mesenchymal shift in GBM

    Vom: 17.5.2024